StockData
AbbVie Inc. logo

AbbVie Inc. (ABBV) operating KPIs

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)

Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%

AbbVie research and development expense ($M) ($M)

Form 10-Q / 10-K

QuarterlyAnnual
Latest, Q2 2026
2,344
Period ended Jun 30, 2026
Change on a year earlier
+10.0%
2,131 in Q2 2025
History
58 quarters
Since Q1 2012
Sources
44
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedResearch and development expense ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20262,344+10.0%Form 10-Q (filed 2026-08-03) ↗
Q1 2026Mar 31, 20262,472+19.6%Form 10-Q (filed 2026-05-08) ↗
Q4 2025Dec 31, 20252,579-61.9%Form 10-K (filed 2026-02-20) ↗
Q3 2025Sep 30, 20252,319+8.9%Form 10-Q (filed 2025-11-04) ↗
Q2 2025Jun 30, 20252,131+9.4%Form 10-Q (filed 2025-08-04) ↗
Q1 2025Mar 31, 20252,067+6.6%Form 10-Q (filed 2025-05-09) ↗
Q4 2024Dec 31, 20246,774+251.5%Form 10-K (filed 2025-02-14) ↗
Q3 2024Sep 30, 20242,130+23.6%Form 10-Q (filed 2024-11-04) ↗
Q2 2024Jun 30, 20241,948+12.4%Form 10-Q (filed 2024-08-07) ↗
Q1 2024Mar 31, 20241,939-15.4%Form 10-Q (filed 2024-05-03) ↗
Q4 2023Dec 31, 20231,927+7.7%Form 10-K (filed 2024-02-20) ↗
Q3 2023Sep 30, 20231,723+6.8%Form 10-Q (filed 2023-11-06) ↗
Q2 2023Jun 30, 20231,733+7.7%Form 10-Q (filed 2023-08-07) ↗
Q1 2023Mar 31, 20232,292+53.1%Form 10-Q (filed 2023-05-05) ↗
Q4 2022Dec 31, 20221,790-2.0%Form 10-K (filed 2023-02-17) ↗
Q3 2022Sep 30, 20221,614-2.8%Form 10-Q (filed 2022-11-04) ↗

Cite this data

StockData. (2026). AbbVie Research and development expense ($M) ($M), quarterly Q1 2012–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/fs_rd

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.